| abstract |
The present application describes novel uracil derivatives of formula I:n nA-W-U-X-Y-Z-U a -X a -Y a -Z a In n or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, W, U, X, Y, Z, U a , X a , Y a , and Z a are defined in the present specification, which are useful as inhibitors of TNF-α converting enzyme (TACE), matrix metalloproteinases (MMP), aggrecanase or a combination thereof. |